IR 5 mg PO BID-TID; ER 5-10 mg PO daily, titrate; transdermal patch 3.9 mg/d twice weekly (OTC)
preparations
String
5 mg IR tablets; 5, 10, 15 mg ER tablets; 5 mg/5 mL syrup; 3.9 mg/24 h transdermal patch (Oxytrol); 10% topical gel
fda_max
String
30 mg/d (XL) typical
pill_id
Text
routes
List of String, delimiter: ,
Oral • transdermal • topical gel • intravesical
onset
String
30-60 minutes (PO)
duration
String
IR: 6-10 hours; ER: 24 hours
halflife
String
2-3 hours (parent and active N-desethyl metabolite)'"`UNIQ--ref-000006E1-QINU`"'
bioavailability
String
~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"'
pregnancy
String
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup>
legal
String
OTC (transdermal patch in women) and [[USLegal:Prescription only|Rx-only]] (other forms) in US
